RBC Capital Markets increased its price target for CorMedix Inc. from $14 to $15 after the Heron Therapeutics deal.

Nov 10, 2026, 5:47 PM ETOpinionRead the original at marketscreener.com

Good for CRMD

RBC raised its share-price target and kept its Outperform rating, supporting a positive reading. It also flagged speculative risk in CorMedix's business model.

CRMD · CorMedix Inc.

AI read · Good for CRMD

The AI's read

The higher target reflects RBC's updated view after CorMedix announced the Heron asset deal. The firm also flagged speculative risk, so this is a favorable analyst opinion, not proof that results will improve.

Get alerts for CRMD

Follow CorMedix Inc. (CRMD) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CRMD

Free on the App Store and Google Play, or on the web.